Fundraising Fox㈜진씨커
1 known investors
Find your way into ㈜진씨커
GeneCker develops liquid biopsy diagnostic technology based on CRISPR/Cas9, using its gcCas9 method to cut wild-type DNA so that target mutant DNA is amplified for detection. The company works on standardizing genetic mutation detection for clinical diagnosis.
Investors · 1
Frequently asked questions
- What does ㈜진씨커 do?
- GeneCker develops liquid biopsy diagnostic technology based on CRISPR/Cas9, using its gcCas9 method to cut wild-type DNA so that target mutant DNA is amplified for detection. The company works on standardizing genetic mutation detection for clinical diagnosis.
- Who are ㈜진씨커's investors?
- ㈜진씨커's investors include SBI Investment Korea Co. Ltd..